GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Beijing Beilu Pharmaceutical Co 300016.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

7.92

-0.25%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Beijing Beilu Pharmaceutical Co

Its shares trade on Shenzhen under the ticker 300016.SZ. It has been listed since 30 October 2009. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.21bn and net income of CN¥92.7m. At that date it held total assets of CN¥3.35bn and shareholders' equity of CN¥2.26bn.

Beijing Beilu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of contrast agents, and central nervous system and hypoglycemic drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2009-10-30. The Company’s main products include gadopentetate dimeglumine injection, iohexol injection, Iodoparol injection, Iodixanol injection, ferric ammonium citrate effervescent granules, repaglinide tablets, glimepiride tablets, Jiuwei Zhenxin granules, among others. The firm mainly distributes its products in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
30 Oct 2009
Employees
923

Leadership

Pay as last reported

  • Mr. Daixue WangChairman of the Board, since 2001CN¥541,800
  • Mr. Xianzhu DuanVice Chairman of the Board, since 1997CN¥745,600
  • Mr. Hong LiChief Financial Officer, Director, since 2001CN¥311,600
  • Ms. Xiasi KuangChief Human Resource Officer, Deputy General Manager, since 2020
  • Mr. Xu WangGeneral Manager
  • Ning LiuDeputy General Manager, Secretary of the BoardCN¥252,100
  • Mr. Zhongjun SuDirector
  • Guo'an FengIndependent DirectorCN¥20,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 923 full-time employees.
  • Headquartered in Beijing, China.
  • Offers a range of pharmaceutical products including contrast agents and CNS drugs.

Weaknesses

  • Mainly distributes products in the domestic market.
  • No international market presence mentioned.
  • Limited product diversity beyond core pharmaceuticals.

Opportunities

  • Potential for expanding into international markets.
  • Growth in demand for contrast agents and CNS drugs.
  • Opportunities in developing new pharmaceutical products.

Threats

  • Dependence on domestic market for sales.
  • Competition in the pharmaceutical industry.
  • Regulatory challenges in the healthcare sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.